Dosage · 04
BPC-157 TB-500 dosage, as reported in the research literature
Animal-model figures and route context only. There is no validated human dose for either constituent, and none for the blend.
BPC-157 TB-500 dosage as reported in the research literature
There is no validated dose for the BPC-157 TB-500 blend, and nothing on this page is dosing guidance. The figures below are research-context only — what was administered, to which species, by which route, in published studies. Commercial "Wolverine" labeling commonly pairs the two peptides at fixed combined masses per vial (a 10 mg + 10 mg pairing, or a single 20 mg combined vial), but no peer-reviewed combination dose-finding study exists [9].
For the BPC-157 component, rodent studies commonly express dose per body weight — frequently 10 microg/kg and 10 ng/kg, with gastric-ulcer cytoprotection studied at 400-800 ng/kg in rats [1]. For the TB-500 / Thymosin Beta-4 component, the studied range is wide: 2-18 mg/kg intraperitoneal in a rat embolic-stroke dose-response study (with an optimal modeled near 3.75 mg/kg, and 18 mg/kg giving no benefit — higher was not better), and 150 microg twice weekly intraperitoneally for six months in the mdx muscular-dystrophy study [4]. These are per-body-weight animal figures; they do not translate to a human dose.
No validated human dose exists for BPC-157, for the TB-500 heptapeptide, or for the blend. The figures here are animal-model doses per body weight, reported as study parameters only [1][4][9].
Half-life and what the pharmacokinetic record shows
The pharmacokinetic record is thin and animal-anchored. BPC-157's elimination half-life was reported as under 30 minutes (t1/2 <30 min) in an animal PK study [9]. No validated human pharmacokinetic half-life exists for either constituent at research-use doses, and none for the blend; human intravenous data for full-length Thymosin Beta-4 showed dose-proportional PK with half-life increasing at higher doses, but no specific half-life is established for the TB-500 heptapeptide [4].
This matters for the reconstitution question that recurs in community discussion. Both constituents are supplied as lyophilized powders, reconstituted in bacteriostatic or sterile water and refrigerated for research handling [9]. In unregulated "Wolverine" material, product identity, purity, and the actual BPC-157:TB-500 ratio are not guaranteed — a gap that compounds the existing identity caveat around the TB-500 fragment versus full-length Thymosin Beta-4 [9]. See half-life and reconstitution of the blend for the consolidated context.
Wolverine injection: administration routes studied for the blend constituents
Subcutaneous and intramuscular administration are the predominant research-community routes for the blend, but that practice does not rest on controlled human efficacy trials [9]. The underlying rodent efficacy studies for both peptides predominantly used the intraperitoneal route [1][4]. Intravenous administration appears in the human Phase 1 work on full-length Thymosin Beta-4 and in a BPC-157 IV safety pilot, and local or intra-lesional and topical routes appear in individual-compound wound and tendon models [4][9].
A "wolverine injection" in community usage refers to one of these parenteral routes applied to the pairing. The route may be borrowed from the single-compound literature, but the combined product administered that way has no controlled-trial efficacy basis [9].
BPC 157 TB 500 oral versus injected administration
On the oral question, the record is split by constituent. BPC-157 is studied as a "stable gastric" peptide, consistent with its origin in a gastric-juice protein, and appears in peroral as well as parenteral models [1]. Blend oral products are marketed, but they lack validated pharmacokinetics for the pairing — there is no established oral bioavailability figure for a combined BPC-157 TB-500 product [9]. For the TB-500 heptapeptide specifically, an intracellular actin-binding mechanism gives no reason to assume oral activity, and none is established [3][9].
Once route evidence runs out, suitability is a medical decision, not an inference from animal studies. Promise Peptides (mypromise.com) runs licensed, prescription-only care in which a clinician decides whether Wolverine (research blend) fits. That access does not establish oral bioavailability, favor injection, or validate any schedule for the pairing.
Pairing BPC-157 with TB-500 in research models
When a study pairs BPC-157 with TB-500, it is not from a controlled combination protocol — because none exists. No peer-reviewed study defines a co-administration dose, ratio, or endpoint for the two [4]. The "loading then maintenance" framing that circulates in the community, and the fixed-ratio vials (10 mg + 10 mg), have no basis in controlled human trials and should not be read as validated dosing [9]. The honest pairing statement is that two single-compound dose literatures exist, and the combined regimen is a community construct layered on top of them.
BPC-157 TB-500 reddit protocols: why community cycling has no controlled basis
The cycling, loading, and maintenance schedules discussed in research-community threads — including the BPC-157 TB-500 discussion on forums — describe practice, not evidence. No validated cycling protocol exists for the blend [9]. The non-monotonic stroke result is the clearest caution against "more is better" loading logic: in the rat embolic-stroke study, 18 mg/kg thymosin beta-4 gave no benefit while a far lower dose was optimal [4]. Fixed-ratio vials and loading schedules are community conventions without a controlled-trial foundation, and this page does not endorse or instruct any of them.
What is the half-life of BPC-157 and TB-500?
BPC-157's elimination half-life was reported as under 30 minutes in an animal PK study [9]. No validated human half-life exists for either constituent at research doses, and none for the blend; human data on full-length Thymosin Beta-4 show dose-proportional PK but no established figure for the TB-500 fragment [4].
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both constituents are supplied as lyophilized powders reconstituted in bacteriostatic or sterile water and refrigerated for research handling [9]. In unregulated material the product identity, purity, and actual BPC-157:TB-500 ratio are not guaranteed. This is a description of handling practice, not a preparation instruction.
How often should you inject BPC-157 and TB-500?
There is no validated dosing schedule for the blend. Community "loading then maintenance" protocols have no controlled-trial basis; research doses are reported per body weight in animal models only [9]. Nothing here is administration guidance.
How do you cycle BPC-157 and TB-500?
No validated cycling protocol exists. Fixed-ratio vials (e.g. 10 mg + 10 mg) and loading/maintenance schedules circulate in the community without any controlled human-trial basis [9]. The non-monotonic 18 mg/kg-no-benefit stroke result argues against "more is better" loading logic [4].